PREDICTIVE TECHNOLOGY GROUP, INC.

Consolidated Balance Sheet
Six Months Ending February 29, 2016
(Unaudited)

BALANCE SHEET

	February 29, 2016 (Unaudited)
Assets:	
Cash and Cash Equivalents	$ 14,727
Office Equipment Net of Depreciation	3,315
Total Current Assets	18,042
License Agreements (Note 2&3)	5,442,791
Intellectual Property (Note 2&3)	306,000,000
Portfolio Investment (Note 3)	16,331,912
Total Assets	$ 327,792,745
LIABILITIES AND EQUITY	
Liabilities:	
Accounts Payable	$ 25,000
Due to License Agreements	1,550,000
Total Current Liabilities	1,575,000
Long-Term Liabilities:	
Deferred Tax Liability	$147,703,000
Total Liabilities	$149,278,000
Equity:	
Common stock, Par Value $0.001, 900,000,000 Shares Authorized, 123,519,012 Shares Issued and Outstanding	123,519
Paid in Capital	178,505,034
Retained Earnings	(113,808)
Total Liabilities and Equity	$ 327,792,745

See accompanying notes to financial statements

PREDICTIVE TECHNOLOGY GROUP, INC.

Consolidated Statement of Operations
Six Months Ending February 29, 2016
(Unaudited)

STATEMENT OF OPERATIONS

	February 29, 2016 (Unaudited)
Revenues:	$ -
Expenses:	
General and Administrative	113,808
Total Expenses	113,808
Net Loss	$ (113,808)

See accompanying notes to financial statements

PREDICTIVE TECHNOLOGY GROUP, INC.

Consolidated Cash Flow

Six Months Ending February 29, 2016

(Unaudited)

STATEMENT OF CASH FLOWS

	February 29, 2016 (Unaudited)
Cash Flows from Operating Activities:	
Net Income (Loss)	$ (113,808)
Adjustments to Reconcile Net Cash Provided by Operating Activities:	
Depreciation and Amortization	368
Net Cash Provided by (Used) by Operating Activities	(113,400)
Cash Flows from Investing Activities:	
Capital Expenditures	(1,602,881)
Net Cash Provided (Used) by Investing Activities	(1,602,881)
Cash Flow from Financing Activities:	
Contributions of Capital	139,823
Due to and from Subsidiaries	-
Due on Patents and Licenses	1,575,000
Net Cash Provided (Used) by Financing Activities	1,714,823
Net Increases (Decrease) in Cash:	(1,498)
Cash at Beginning of Period	16,225
Cash at End of Period	14,727

See accompanying notes to financial statements.

PREDICTIVE TECHNOLOGY GROUP, INC.

Financial Notes

For The Six Months Ending February 29, 2016

NOTE 1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Operations: Predictive Technology Group, Inc. (PRED) is in the business of developing and implementing novel medical solutions to a number of aliments which commonly afflict individuals domestically and worldwide. PRED's quest is to improve lives by indentifying, developing, acquiring and commercializing medical apparatuses and treatments that address human medical needs.

Basis of Presentation. Predictive Technology Group, Inc prepared its combined financial statements in accordance with accounting principles generally accepted in the United States of America. These combined financial statements include the results of operations. Accordingly, the financial statements for Predictive Technology Group, Inc. have been combined for the six months ending February 29, 2016.

Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements. Predictive Technology Group, Inc. does not believe that there are any other new pronouncements that have been issued that might have a material impact on its combined financial position or combined results of operations.

Cash and Cash Equivalents. Predictive Technology Group, Inc. considers all highly liquid investments purchased with an original maturity of twelve months or less to be cash equivalents.

Income Taxes. Deferred tax assets and liabilities are recorded to reflect the future tax consequences attributable to the effects of differences between the carrying amounts of existing assets and liabilities for financial reporting and for income tax purposes. Deferred taxes are calculated by applying enacted statutory tax rates and tax laws to future years in which temporary differences are expected to reverse. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate change is enacted.

NOTE 2- INTELLECTUAL PROPERTY & LICENSE AGREEMENTS

Predictive Technology Group, Inc. through its acquisitions of Predictive Therapeutics, LLC has a number of patents and license agreements categorized under "Intellectual Property" and "Licenses Agreements." The acquisition of Predictive Therapeutics, LLC and those patents associated with this acquisition have an asset valuation at $306,000,000, and the related license agreements have a combined asset valuation of $5,442,791. The total asset valuation of the "Intellectual Property" and "License Agreements" equals $311,442,791. These valuations are estimates by the Company's management, formulated on the number of shares exchanged for these assets at predetermined market share prices negotiated at the time of this acquisition.

The table below provides comprehensive overviews of the intellectual properties related to each of the patents and licenses:

ENDOMETRIOSIS THERAPEUTIC – NHP-07
Owned by Predictive Therapeutics, LLC (No contingencies or royalty obligations)

Title	Ser #, Patent # or Pub#		1st Name Inventor	Status
Progestin Cannabis Therapeutic and Method of Use	14/281,172 US 9,149,499	US	Bradley C. Robinson	Issued
Progestin NSAID Therapeutic and Method of Use	14/281,127 US 9,161,941	US	Bradley C. Robinson	Issued
Progestin NSAID Therapeutic and Method of Use	PCTUS2014386018	US	Bradley C. Robinson	National Filing Stage
Progestin NSAID Therapeutic and Method of Use	14/875,656 US 2016/0022696	US	Bradley C. Robinson	Pending
Method of Treating Endometriosis	62/275,413	US	Bradley C. Robinson	Pending
Additional US and International filings in process				

ENDOMETRIOSIS GENETIC DIAGNOSTIC
Licensed from Juneau Biosciences, LLC (profit sharing)

Title	Ser #, Patent # or Pub #		1st Named Inventor	Status
Genetic Markers Associated with Endometriosis and Use Thereof	12/765,643 US 2010/0272713	US	Kenneth Ward	Pending
Genetic Markers Associated with Endometriosis and Use Thereof	13/159,132 US 2015/0361494	US	Kenneth Ward	Pending
Method of Determining Predisposition of Endometriosis	13/603,284 US 2015/0363558	US	Kenneth Ward	Pending
Method of Determining Predisposition of Endometriosis	13/788,913 US 8,932,993	US	Kenneth Ward	Issued
Method of Testing for Endometriosis and Treatment Thereof	13/789,082 US 2015/0368714	US	Kenneth Ward	Pending
Method of Testing for Endometriosis and Treatment Thereof	14/594,266 US 2015/0133382	US	Kenneth Ward	Pending
Additional US and International filings in process				

SPINE TECHNOLOGIES
Owned by Predictive Therapeutics, LLC (No contingencies or royalty obligations)

Title	Ser #, Patent # or Pub #		1st Named Inventor	Status
Apparatus and Method for Dynamic Scoliosis Orthosis	12/145,959 US 7,967,767	US	Ogilvie	Issued
Method of Treating Scoliosis Using a Biological Implant and Determining Predisposition	12/341,289 US 8,123,787	US	Ogilvie	Issued
Method of Treating Scoliosis Using a Biological Implant and Determining Predisposition	13/357,800 US 8,641,738	US	Ogilvie	Issued
Method of Treating Spinal Deformity Using a Biological Implant and Determining Predisposition	14/170,691 US 2105/0127105	US	Ogilvie	Notice of Allowance Received
Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof	13/364,378 US 2105/0337373	US	Chettier	Pending
Additional US and International filings in process				

NOTE 3. - STOCKHOLDERS' EQUITY

During the six months ending February 29, 2016, the Company had 123,519,012 shares issued and outstanding. In addition, options for 650,000 shares have been granted, subject to performance and service period requirements.

Predictive Technology Group, Inc. on April 15, 2015 announced the Company entered into an agreement to acquire a majority position of Predictive Therapeutics, LLC. On February 16, 2016 Management announced acquiring the remaining 16% of Predictive Therapeutics, LLC and at that time it became a wholly owned subsidiary of the Company.

On January 26, 2016, the Company announced the acquisition of LifeCode Genetics, Inc. as its wholly owned subsidiary. Since 2011, LifeCode Genetics, Inc. develops and commercializes gene based diagnostics and held a strategic equity investment of 10.12% (approx.) in Juneau Biosciences, LLC. Once the acquisition occurred, this 10.12% (approx.) ownership became Predictive Technology Group, Inc., and is recorded as a "Portfolio Investment" with an asset valuation of $16,331,192.

On July 16, 2015, the State of Nevada approved a corporate name change to Predictive Technology Group, Inc. and 900,000,000 shares where authorized. The Corporation's board minutes approving this action and majority shareholders presented their shareholders' consent for both of these corporate actions approved by the Secretary of State of Nevada;

The Company is an active corporation in the State of Nevada with its current officer and directors as Mr. Bradley Robinson, Director, CEO and President, and Mr. Merle Ferguson, Chairman, Treasurer and Secretary.

NOTE 4. – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the out come of this uncertainty.